在癌症萌芽时进行 SNP 检测：miRNA 和 miRNA 靶位多态性作为癌症的诊断和预后生物标志物。
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.
机构信息
Department of Therapeutic Radiology, Yale School of Medicine, 15 York Street, Hunter Building, HRT-205, New Haven, CT 06510, USA.
出版信息
Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3.
Abstract
MicroRNAs are master regulators of gene expression and control many biological pathways such as cell growth, differentiation and apoptosis. Deregulation of microRNA expression and activity results in a myriad of diseases including cancer. Recently, several reports have indicated that single nucleotide polymorphisms (SNPs) in microRNAs and microRNA-target sites impact microRNA biology and associate with cancer risk, treatment response and outcome. In this review we will describe these findings and discuss the possible future of utilizing these SNPs as diagnostic and prognostic markers in the clinic.
摘要
微小 RNA 是基因表达的主要调控因子，控制着许多生物学途径，如细胞生长、分化和凋亡。微小 RNA 表达和活性的失调导致了许多疾病，包括癌症。最近，有几项报告表明，微小 RNA 及其靶位点的单核苷酸多态性 (SNPs) 会影响微小 RNA 的生物学特性，并与癌症风险、治疗反应和预后相关。在这篇综述中，我们将描述这些发现，并讨论将这些 SNPs 作为临床诊断和预后标志物的可能未来。
相似文献
1
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.在癌症萌芽时进行 SNP 检测：miRNA 和 miRNA 靶位多态性作为癌症的诊断和预后生物标志物。
Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3.
2
SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.微小RNA结合位点中的单核苷酸多态性作为癌症的预后和预测生物标志物。
Crit Rev Oncog. 2013;18(4):327-40. doi: 10.1615/critrevoncog.2013007254.
3
Functional microRNA binding site variants.功能性 microRNA 结合位点变异。
Mol Oncol. 2019 Jan;13(1):4-8. doi: 10.1002/1878-0261.12421. Epub 2018 Dec 26.
4
Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.微标志物2.0：微小RNA在癌症诊断和预后中的作用更新
Expert Rev Mol Diagn. 2015;15(10):1369-81. doi: 10.1586/14737159.2015.1081058. Epub 2015 Sep 4.
5
MicroRNAs in cancer: biomarkers, functions and therapy.微小 RNA 与癌症：生物标志物、功能与治疗。
Trends Mol Med. 2014 Aug;20(8):460-9. doi: 10.1016/j.molmed.2014.06.005. Epub 2014 Jul 12.
6
Genetic variation in microRNA networks: the implications for cancer research.miRNA 网络中的遗传变异：对癌症研究的影响。
Nat Rev Cancer. 2010 Jun;10(6):389-402. doi: 10.1038/nrc2867.
7
Identification of diagnostic and prognostic biomarkers for cancer: Focusing on genetic variations in microRNA regulatory pathways (Review).癌症诊断和预后生物标志物的鉴定：聚焦于微小RNA调控途径中的基因变异（综述）
Mol Med Rep. 2016 Mar;13(3):1943-52. doi: 10.3892/mmr.2016.4782. Epub 2016 Jan 14.
8
Single-nucleotide polymorphisms among microRNA: big effects on cancer.微小RNA中的单核苷酸多态性：对癌症有重大影响。
Chin J Cancer. 2011 Jun;30(6):381-91. doi: 10.5732/cjc.011.10142.
9
Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival.微小RNA、微小RNA靶标和微小RNA生物合成基因中的单核苷酸多态性及其对结直肠癌生存的影响。
Genes Chromosomes Cancer. 2017 Apr;56(4):285-295. doi: 10.1002/gcc.22434. Epub 2017 Jan 25.
10
microRNA-related single-nucleotide polymorphisms and breast cancer.miRNA 相关的单核苷酸多态性与乳腺癌。
J Cell Physiol. 2021 Mar;236(3):1593-1605. doi: 10.1002/jcp.29966. Epub 2020 Jul 27.
引用本文的文献
1
ETV1 genetic polymorphisms as a candidate prognosis biomarker of Gastrointestinal stromal tumor.ETV1基因多态性作为胃肠道间质瘤的候选预后生物标志物
Cancer Chemother Pharmacol. 2025 Jul 2;95(1):68. doi: 10.1007/s00280-025-04789-2.
2
Association of the pri-miR-34b/c rs4938723 T > C polymorphism with hepatoblastoma susceptibility in Eastern Chinese children: A five-center case-control study.中国东部儿童中pri-miR-34b/c rs4938723 T > C多态性与肝母细胞瘤易感性的关联：一项五中心病例对照研究
BMC Med Genomics. 2025 Jul 1;18(1):105. doi: 10.1186/s12920-025-02179-4.
3
Influence of rs Genetic Variant on miR-21 Gene Expression in Patients With Type 1 Diabetes Mellitus: A Case-Control Study.rs基因变异对1型糖尿病患者miR-21基因表达的影响：一项病例对照研究。
Health Sci Rep. 2025 Mar 2;8(3):e70480. doi: 10.1002/hsr2.70480. eCollection 2025 Mar.
4
Polymorphism in the Hsa-miR-4274 seed region influences the expression of PEX5 and enhances radiotherapy resistance in colorectal cancer.Hsa-miR-4274 种子区的多态性影响 PEX5 的表达并增强结直肠癌的放射抵抗性。
Front Med. 2024 Oct;18(5):921-937. doi: 10.1007/s11684-024-1082-6. Epub 2024 Aug 27.
5
Novel polymorphism rs12402181 in the mature sequence of hsa-miR-3117-3p has a protective effect against breast cancer development by affecting miRNA processing and function.人源微小RNA-3117-3p（hsa-miR-3117-3p）成熟序列中的新型多态性位点rs12402181通过影响微小RNA的加工和功能，对乳腺癌的发生发展具有保护作用。
3 Biotech. 2023 Nov;13(11):349. doi: 10.1007/s13205-023-03765-y. Epub 2023 Sep 29.
6
Association of miRNA targetome variants in LAMC1 and GNB3 genes with colorectal cancer and obesity.LAMC1 和 GNB3 基因中 miRNA 靶标变体与结直肠癌和肥胖的关联。
Cancer Med. 2022 Nov;11(21):3923-3938. doi: 10.1002/cam4.4713. Epub 2022 Apr 4.
7
Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells.miRNA-423 基因变异促进乳腺癌细胞的增殖、迁移、侵袭和化疗耐药性。
Int J Mol Sci. 2021 Dec 29;23(1):380. doi: 10.3390/ijms23010380.
8
Polymorphism rs2682818 participates in the progression of colorectal carcinoma via miR-618-TIMP1 regulatory axis.多态性 rs2682818 通过 miR-618-TIMP1 调节轴参与结直肠癌的进展。
Sci Rep. 2021 Nov 30;11(1):23186. doi: 10.1038/s41598-021-02613-4.
9
An in silico approach to identify and prioritize miRNAs target sites polymorphisms in colorectal cancer and obesity.一种基于计算机的方法，用于鉴定和优先考虑结直肠癌和肥胖症中 miRNA 靶位点多态性。
Cancer Med. 2020 Dec;9(24):9511-9528. doi: 10.1002/cam4.3546. Epub 2020 Oct 18.
10
Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer .全基因组关联研究的批判性分析：三阴性乳腺癌
Int J Mol Sci. 2020 Aug 14;21(16):5835. doi: 10.3390/ijms21165835.
本文引用的文献
1
Genetic variants in miRNAs predict bladder cancer risk and recurrence.miRNA 中的遗传变异可预测膀胱癌风险和复发。
Cancer Res. 2012 Dec 1;72(23):6173-82. doi: 10.1158/0008-5472.CAN-12-0688. Epub 2012 Jul 30.
2
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.KRAS 变异与发生双重原发性乳腺癌和卵巢癌的风险相关。
PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.
3
The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.miRNA 结合位点多态性在 DNA 修复基因中作为膀胱癌和乳腺癌的风险因素及其对放疗结果的影响。
Carcinogenesis. 2012 Mar;33(3):581-6. doi: 10.1093/carcin/bgr300. Epub 2011 Dec 12.
4
MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.miR-146a 通过靶向 EGFR 通路并以依赖于 p-ERK 的方式抑制去势抵抗性前列腺癌中的肿瘤生长和进展。
Prostate. 2012 Aug 1;72(11):1171-8. doi: 10.1002/pros.22466. Epub 2011 Dec 7.
5
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.KRAS 变异是一种不良预后、铂类化疗耐药的生物标志物，也是卵巢癌治疗的潜在靶点。
Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.
6
MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes.MicroRNA 失稳使得 miR-16 家族能够响应细胞周期变化进行动态调节。
Mol Cell. 2011 Sep 16;43(6):993-1004. doi: 10.1016/j.molcel.2011.08.021.
7
MicroRNA signatures differentiate melanoma subtypes.微小 RNA 特征可区分黑色素瘤亚型。
Cell Cycle. 2011 Jun 1;10(11):1845-52. doi: 10.4161/cc.10.11.15777.
8
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.3'-非翻译区 KRAS 变异与三阴性乳腺癌：病例对照与遗传分析。
Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22.
9
dPORE-miRNA: polymorphic regulation of microRNA genes.dPORE-miRNA：miRNA 基因的多态性调控。
PLoS One. 2011 Feb 4;6(2):e16657. doi: 10.1371/journal.pone.0016657.
10
miRBase: integrating microRNA annotation and deep-sequencing data.miRBase：整合微小RNA注释与深度测序数据
Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7. doi: 10.1093/nar/gkq1027. Epub 2010 Oct 30.
Zotero 插件